Skip to main content
SpringerLink
Log in

Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats

  • Original Article
  • DFO, ICRF-187, Doxorubinin-Induced Toxicity, Iron Chelation
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Since the iron-mediated formation of free radicals is considered to be a critical factor in the pathogenesis of the toxicity of doxorubicin (DXR), comparisons were made of the protective effects of two iron chelators, ICRF-187 and desferrioxamine (DFO), against the chronic cardiac and renal toxicity induced by DXR in spontaneously hypertensive rats (SHR). Two preparations of DFO were studied: DFO mesylate (DFO-M) and a polymeric form (DFO-P) in which DFO is conjugated to hydroxyethyl starch. Groups of 5 SHR each were given 12 weekly i.v. injections of 1 mg/kg DXR either alone or 30 min after the i.p. injection of 25 mg/kg ICRF-187, 50 mg/kg DFO-M, 50 mg/kg DFO-P, or 100 mg/kg DFO-P. A semiquantitative assessment was made of the cardiomyopathy (Billingham scale) and nephropathy. Renal protection was minimal with DFO-M and moderate with ICRF-187 and both doses of DFO-P. There was no cardiac protection with DFO-M. Both doses of DFO-P provided similar but modest degrees of cardiac protection. DXR-induced mortality was not prevented by either preparation of DFO. ICRF-187 provided a higher degree of protection against the cardiotoxicity and the mortality induced by DXR. Since both DFO and ICRF-187 are highly efficient chelators of iron in vitro, the differences in their in vivo protective effects are thought to be related to their cellular uptake and intracellular distribution and to the relative availability of different intracellular iron pools to these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Al-Harbi MM, Al-Gharably NM, Al-Shabanah OA, Al-Bekairi AM, Osman AMM, Tawfik HN (1992) Prevention of doxorubicininduced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol 31:200

    Google Scholar 

  2. Billingham ME (1991) Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver MD (ed) Cardiovascular pathology, 2nd edn. Churchill Livingstone, New York, p 1465

    Google Scholar 

  3. Blum RH, Carter SK (1974) Adriamycin: a new antitumor drug with significant clinical activity. Ann Intern Med 80:244

    Google Scholar 

  4. Butler J, Halliwell B (1982) Reaction of iron-EDTA chelates with the superoxide radical. Arch Biochem Biophys 218:174–178

    Google Scholar 

  5. Cederbaum AI, Dicker E (1983) Inhibition of microsomal oxidation of alcohols and of hydroxyl-radical-scavenging agents by the iron-chelating agent desferrioxamine. Biochem J 210:107

    Google Scholar 

  6. Crichton RR, Roman F, Roland F (1980) Iron mobilization from ferritin by chelating agents. J Inorg Biochem 13:305

    Google Scholar 

  7. Deighton N, Hider RC (1989) Purification and characterization of a low molecular weight iron complex isolated from rat liver. Biochem Soc Trans 17:490

    Google Scholar 

  8. Demant EJF (1983) NADH oxidation in submitochondrial particles protects respiratory chain activity against damage by adriamycin-Fe3+. Eur J Biochem 137:113

    Google Scholar 

  9. Demant EJF, Jensen PK (1983) Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur J Biochem 132:551

    Google Scholar 

  10. Doroshow JH (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460

    Google Scholar 

  11. Doroshow JH, Burke TG, VanBalgoony J, Akmans, Verhoef V (1991) Cellular pharmacology of ICRF-187 (ADR-529) in adult rat heart myocytes. Proc Am Assoc Cancer Res 32:332

    Google Scholar 

  12. El-Hage A, Herman EH, Yang GC, Crouch RK, Ferrans VJ (1986) Mechanisms of the protective effect of ICRF-187 against alloxaninduced diabetes in mice. Res Commun Chem Pathol Pharmacol 52:341

    Google Scholar 

  13. Feldman JE, Jones SE, Weisberg SR, Gandara DR, Lyman GH, York RM, Malliard JA, Hayes DM, Tranum B, Spaulding MB, Shaikh BS, Khojasteh A, Wajima T, Rivers RR, Abramson N, Horvath WL, Pendergrass KB, Reynolds RD, Gerber M, Winston J, Squillance K, Kline A, Swearengin B, Hess D, Scott D, Banks PLC, Jones D, Bianchine J, Gams RA (1992) Advanced small cell lung cancer treated with CAV (cyclophosphamide + adriamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR529, ICRF-187, ZINECARD). Proc Am Soc Clin Oncol 11:796

    Google Scholar 

  14. Fukuda Y, Herman EH, Ferrans VJ (1992) Effect of ICRF-187 on pulmonary damage induced by hyperoxia in the rat. Toxicology 74:185

    Google Scholar 

  15. Gianni L, Myers CE (1992) The role of free radical formation in the cardiotoxicity of anthracyclines. In: Muggia FM, Green MD, Speyer JL (eds) Cancer treatment and the heart. Johns Hopkins University Press, Baltimore, p 9

    Google Scholar 

  16. Gutteridge JMC, Richmond R, Halliwell B (1979) Inhibition of the iron-catalyzed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J 184:469

    Google Scholar 

  17. Hallaway PE, Eaton JW, Panter SS, Hedlund BE (1989) Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proc Natl Acad Sci USA 86:10108

    Google Scholar 

  18. Halliwell B (1985) Use of desferrioxamine as a “probe” for iron dependent formation of hydroxyl radicals. Evidence for a direct reaction between desferal and the superoxide radical. Biochem Pharmacol 34:229

    Google Scholar 

  19. Halliwell B (1989) Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Rad Biol Med 7:645

    Google Scholar 

  20. Hasinoff BB (1989) The interaction of the cardioprotectant agent ICRF-187(+)-1, 2-bis(3,5-dioxopiperazinyl-1-y)propane): its hydrolysis product (ICRF-198) and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26:378

    Google Scholar 

  21. Hasinoff BB, Kala SV (1993) The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187[(+)-1, 2-bis(3, 5 dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR925. Agents Actions 39:72

    Google Scholar 

  22. Herman EH, El-Hage AN, Ferrans VJ, Ardalan B (1985) Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 78:202

    Google Scholar 

  23. Herman EH, El-Hage A, Ferrans VJ (1988) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92:42

    Google Scholar 

  24. Herman EH, El Hage A, Fukuda Y, Ferrans VJ (1989) ICRF-187 reduces bleomycin-induced pulmonary toxicity in mice. FASEB J 3:A275

    Google Scholar 

  25. Herman EH, Ferrans VJ, Sanchez JA (1992) Methods of reducing the cardiotoxicity of anthracyclines. In: Muggia FM, Green MD, Speyer JL (eds) Cancer treatment and the heart. Johns Hopkins University Press, Baltimore, p 114

    Google Scholar 

  26. Hershko C, Link C, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A (1993) Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122:245

    Google Scholar 

  27. Hoe S, Rowley DA, Halliwell BA (1982) Reactions of ferrioxamine and desferrioxamine with the hydroxyl radical. Chem Biol Interact 41:75

    Google Scholar 

  28. Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 119:758

    Google Scholar 

  29. Klabanoff SJ, Waltersdorph AM, Michel BR, Rosen H (1989) Oxygen-based free radical generation by ferrous ions and deferoxamine. J Biol Chem 264:19765

    Google Scholar 

  30. Kleber EE, Torrence JD, Bothwell TH, Simon MO, Charlton RW (1981) Mobilization of iron from peritoneal rat macrophages by desferrioxamine. Scand J Haematol 27:209

    Google Scholar 

  31. Kruskal WH, Wallis WA (1952) Use of ranks in one criterion variance analysis. J Am Stat Assoc 47:583

    Google Scholar 

  32. Lefrak EA, Pitha J, Rosenheim S, O'Bryan RM, Burgess MA, Gottlieb JA (1975) Adriamycin (NSC 123127) cardiomyopathy. Cancer Chemother Rep 6:203

    Google Scholar 

  33. Lind MD, Hamor MJ, Hamor TA, Hoard JL (1964) Stereochemistry of ethylene diaminetetraaceto complexes. Inorg Chem 3:34

    Google Scholar 

  34. Lloyd JB, Cable H, Evans CR (1991) Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 42:13615

    Google Scholar 

  35. Mettler FP, Young DM, Ward JM (1977) Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37:2705

    Google Scholar 

  36. Mhatre RM, Rahman A, Raschid S, Schein PS (1982) Pharmacokinetic and tissue distribution of ICRF-187 in mice. Proc Am Assoc Cancer Res 23:212

    Google Scholar 

  37. Mhatre RM, Tew KD, Van Hennik MB, Waravdekar VS, Schein PS (1983) Absorption, distribution and pharmacokinetics of ICRF-187 in dogs. Proc Am Assoc Cancer Res 24:290

    Google Scholar 

  38. Myers CE, Gianni L, Simone CB, Klecker R, Greene R (1982) Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 21:1707

    Google Scholar 

  39. Myers C, Gianni L, Zweier J, Munindi J, Shina BK, Eliot H (1986) Role of iron in adriamycin biochemistry. Fed Proc 45:2792

    Google Scholar 

  40. Osman AMM, Al-Shabanah OA, Al-Harbi MM, Al-Gharably NM, Al-Bekairi AM, Tawtik HN, Aziz SA (1993) Effect of desferrioxamine on doxorubicin-induced cardio- and haemato-toxicity in normal mice. Med Sci Res 21:193

    Google Scholar 

  41. Rajagopalan S, Potiti PM, Sinha BK, Myers CE (1988) Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48:4766

    Google Scholar 

  42. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward S, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bisdioxopiperazine ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745

    Google Scholar 

  43. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hoschter H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W, Muggia F (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117

    Google Scholar 

  44. Thomas C, Vile GF, Winterbourn CC (1993) The hydrolysis product of ICRF-187 promotes iron-catalyzed hydroxyl radical production via the Fenton reaction. Biochem Pharmacol 45:1967

    Google Scholar 

  45. Voest EE, Van Asbeck BS, Neijt JP, Marx JJM (1993) Deferoxamine inhibits adriamycin-induced cardiotoxicity in the rat. Clin Res 41:309A

    Google Scholar 

  46. Young DM (1975) Pathologic effects of adriamycin (NSC 123127) in experimental systems. Cancer Chemother Rep 6:159

    Google Scholar 

  47. Zhang J, Herman EH, Ferrans VJ, (1993) Dendritic cells in hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 142:1916

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Research and Testing, Food and Drug Administration (HFD-472), 8301 Muirkirk Road, 20708, Laurel, MD, USA

    E. H. Herman & Jun Zhang

  2. Ultrastructure Section, Pathology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

    Victor J. Ferrans

Authors
  1. E. H. Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victor J. Ferrans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herman, E.H., Zhang, J. & Ferrans, V.J. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 35, 93–100 (1994). https://doi.org/10.1007/BF00686629

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686629

Key words

Search

Navigation